全球药物安全检测市场：市场规模、份额、趋势分析（按产品生命週期、服务供应商、类型、治疗领域、流程、最终用途和地区）、细分市场预测（2025-2030 年）

药物安全检测市场的成长与趋势：

根据 Grand View Research, Inc. 的一份新报告，到 2030 年全球药物安全检测市场规模预计将达到 117.8 亿美元。

预计2025年至2030年期间，该市场的复合年增长率将达到6.5%。市场成长的主要驱动力是药物不良反应 (ADR) 发病率的上升。 ADR 给医疗保健系统带来了巨大的负担，并且是已开发国家疾病高发生率的明显原因之一。根据美国生物技术资讯中心 (NCBI) 的数据，欧洲每年约有20例住院病例是由 ADR 引起的。药物安全检测(PV) 服务在协助製造商识别临床试验阶段药物相关不良反应方面发挥着至关重要的作用。

此外，2022年2月发表在《当代医学研究与实践杂誌》上的一篇题为《癌症化疗患者不良反应严重性和结局的特征——一项前瞻性观察性研究》的论文显示，严重的药物不良反应每年在美国造成超过10万人死亡，成为过去十年来的主要健康问题。致命的心律不整和肝功能衰竭等药物不良反应可能导致药物退出市场，因为使用这些药物的风险大于其益处。新冠疫情为光电服务供应商带来了机会和挑战，促使他们开发创新平台来提升竞争力。

例如，2020年12月，生命科学产业的商业服务供应商EVERSANA与专注于药物开发流程自动化的生命科学软体公司ArisGlobal合作。此次合作旨在将端到端的药物上市（PV）流程数位化，从而在全球范围内实现更安全、更有效的医疗保健。预计在预测期内，对技术先进且用户友好的软体系统（例如云端基础的药物上市和药物安全平台）的需求将支撑产业成长。例如，Clinevo Technologies提供的Clinevo Safety是一款云端基础的解决方案，涵盖案例处理、法规提交/AS2网关、药物上市（PV）接收、分析和安全讯号等多种功能。

这种一体化平台正在推动市场发展。此外，协调一致的努力也支持巴西等新兴市场的成长。例如，巴西推出了一项联合病患安全和药物警戒 (PV) 项目，涉及製药业、学术界、临床实践和卫生当局。该计画由巴西农业研究基金会 (FIPFARMA) 和圣保罗大学药学院共同实施，分两期（2020 年和 2022 年）推出了一门 30 小时的线上课程。课程涵盖了医疗保健和药物安全检测概述、药物安全和管理以及病人安全文化等重要主题。研讨会探讨了医疗保健专业人员 (HCP) 面临的实际挑战，并鼓励协作解决问题。

视讯会议有效地吸引了医护人员参与并进行了培训，促进了知识共用，并促使思维方式转变。该措施对参与者产生了积极影响，并提升了巴西的药效学实践。已开发国家的大型製药公司正致力于外包药效学服务，以降低成本和营运费用。这有望为开发中国家的合约研究组织 (CRO) 提供扩大其行业份额的机会。开发人员正在重新思考其产品委外研发机构，以满足全球日益增长的患者需求。由于这些因素，预计在预测期内，对药效学服务的需求将会成长。

此外，光伏产业参与者正在实施收购、合作、业务扩张和产品发布等策略，以拓宽产品供应并提升市场份额。例如，专注于製药业的服务供应商Ergomed plc于2022年2月收购了ADAMAS Consulting Group Limited。 ADAMAS是一家国际顾问公司，为光电系统提供药品製造、临床试验审核和品质保证服务。此次收购价值2,560万英镑，预计将增加Ergomed的收益，并在未来带来进一步的成长和策略优势。

药物安全检测市场：概述

• 由于 ADR 事件和上市后监测的增加，IV 期在 2024 年占据市场主导地位，收入份额超过 75.90%。
• 在2024年的服务供应商领域中，合约外包领域占据了最大的市场占有率，因为製药公司旨在透过外包服务来降低业务成本。
• 自发报告部分在 2024 年占据了药物安全检测市场的最大份额。其应用包括高效且经济地检测新型、严重和罕见的 ADR。
• 在2024年的治疗领域细分中，肿瘤学占最大份额，超过27.14%，这得益于生物製药公司在慢性癌症治疗的研究力度。
• 预测期内，案例资料管理预计将在流程流程领域中以最快的复合年增长率成长。
• 由于生物技术公司专注于生技药品、治疗药物和基因疗法等新产品的研发，预计在预测期内生物技术公司部门的复合年增长率将最快。
• 由于对开发新药的投资、有利的法规以及强大的研究单位和临床试验的存在，北美将在 2024 年占据最大的收益占有率，超过 32.11%。
• 公司正在采取新产品发布、合作和收购等策略来获得竞争优势。

目录

第一章 分析方法与范围

第二章执行摘要

第三章 市场驱动因素、趋势与范围

• 市场联动展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制分析
  • 产业机会分析
  • 产业挑战分析
• 波特五力分析
  • 供应商权力
  • 买方力量
  • 替代威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争
• PESTLE分析
• 价值链分析
  • 临床前
  • 临床
  • PMA
• 绘製服务产品生命週期及其需求
• 法律规范
  • 监理机关名单：依国家
• 定价模式
  • 药品安全预算依活动分配
  • 按开发阶段
  • 按治疗区域
  • 定价层
• 技术时间轴概述
  • 技术变革与采用
  • 太阳能技术的现状
  • IQVIA 的人工智慧主导的药物安全检测转型
  • Tech Mahindra 的人工智慧驱动药物安全检测解决方案
  • AI辅助光电工作负载的演进
  • 社群媒体
• COVID-19影响分析
  • 发展与策略成果
• 市场趋势：
  • 扩展资源
  • 药物安全检测自动化
• 通货膨胀的影响
• 案例研究
  • 潜在客户
  • 值得注意的用案例
  • 案例研究1
  • 案例研究2
  • 案例研究3
  • 案例研究4

第四章药物安全检测市场：按产品的估计和趋势分析

• 细分仪表板：依产品
• 按产品分類的市场占有率变化分析（2024 年和 2030 年）
• 市场规模预测及产品趋势分析（2018-2030）
  • 临床前
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第五章药物安全检测市场：服务供应商的估计和趋势分析

• 细分仪表板：依服务供应商
• 服务供应商市场占有率变化分析（2024 年和 2030 年）
• 服务供应商市场规模预测及趋势分析（2018-2030）
• 内部
  • 内部市场（2018-2030）
• 合约外包
  • 合约外包市场（2018-2030）

第六章药物安全检测市场：按类型进行估计和趋势分析

• 细分仪表板：按类型
• 按类型分類的市场占有率变化分析（2024 年和 2030 年）
• 按类型分類的市场规模预测和趋势分析（2018-2030）
• 自发性报告
• 增强型 ADR 报告
• 有针对性和自发性的报道
• 群组心臟事件记录器(CEM)
• EHR挖掘

第七章药物安全检测市场：依流程进行评估与趋势分析

• 细分仪表板：依流程
• 按製程流程分類的市场占有率变化分析（2024 年和 2030 年）
• 按製程流程分類的市场规模预测和趋势分析（2018-2030）
• 病例资料管理
• 讯号检测
• 风险管理系统

第八章药物安全检测市场：按治疗领域的估计和趋势分析

• 细分仪表板：按治疗领域
• 按治疗领域分類的市场占有率变化分析（2024 年和 2030 年）
• 依治疗领域分類的市场规模预测及趋势分析（2018-2030年）
• 瘤
  • 肿瘤学市场（2018-2030）
• 神经病学
  • 神经病学市场（2018-2030）
• 呼吸系统
  • 呼吸系统市场（2018-2030）
• 其他的
  • 其他市场（2018-2030）
• 神经病学

第九章药物安全检测市场：按地区估计和趋势分析

• 市场仪表板：按地区
• 各地区主要市场点
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 俄罗斯
  • 丹麦
  • 瑞典
  • 挪威
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 澳洲
  • 泰国
• 拉丁美洲
  • 巴西
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 科威特

第 10 章药物安全检测市场：竞争分析

• 市场参与企业分类
• 上市公司
  • 企业市场分析
  • 公司市场占有率分析
• 竞争因素和策略
  • 增加策略合作和产品发布
  • 政府策略性倡议，包括合作
  • 竞争对手加强光电宣传计划
  • 竞争正在加强业务协作和外包
  • 整合趋势

第十一章竞争格局

• 公司简介
  • Accenture
  • IQVIA Inc.
  • Cognizant
  • Clinquest Group BV（Linical Americas）
  • IBM
  • Laboratory Corporation of America Holdings
  • ArisGlobal
  • Capgemini
  • ITClinical
  • ICON plc.
  • TAKE Solutions Limited
  • Parexel International（MA）Corporation
  • Wipro
  • United BioSource LLC
  • BioClinica Inc.（Clario）
  • ClinChoice（formerly FMD K&L）

第十二章 制胜策略

• 主要胜利/评分标准
  • 按类别
  • 供应商选择的关键因素

第十三章 转换成本分析

Pharmacovigilance Market Growth & Trends:

The global pharmacovigilance market size is projected to reach USD 11.78 billion by 2030, according to a new report by Grand View Research, Inc. It is anticipated to witness growth at a CAGR of 6.5% from 2025 to 2030. The key factor responsible for the market growth is the growing incidence of Adverse Drug Reactions (ADR). ADR imposes a significant load on healthcare systems and is one of the evident grounds for morbidity in developed nations. As per the National Center for Biotechnology Information (NCBI), about 1 in 20 hospitalizations in Europe yearly are owing to ADR. Pharmacovigilance (PV) services play a vital role in the clinical trial phase by aiding manufacturers in recognizing the negative consequences associated with the drug.

Furthermore, a February 2022 article published in the Journal of Current Medicine Research and Practice titled "Characterization of Seriousness and Outcome of Adverse Drug Reactions in Patients Receiving Cancer Chemotherapy Drugs - A Prospective Observational Study" revealed that serious ADRs in the U.S. result in over 100,000 deaths annually and have been a major health concern since the past decade. ADRs, such as fatal arrhythmia and liver failure, can result in drug withdrawal from the market as the risks related to the drug usage outweigh its associated benefits. The COVID-19 pandemic presented both opportunities and challenges for PV service providers, leading to the development of innovative platforms for a competitive edge.

For instance, in December 2020, EVERSANA, a commercial services provider in the life sciences industry, collaborated with ArisGlobal, a life sciences software company specializing in automating drug development processes. This partnership was aimed to digitally transform end-to-end PV procedures, ensuring safer and more effective healthcare worldwide. The market for technologically advanced and user-friendly software systems, like cloud-based PV and drug safety platforms, is anticipated to support industry growth over the forecast period. For instance, Clinevo Technologies offers Clinevo Safety, a cloud-based solution encompassing various functionalities, such as Case Processing, Regulatory Submissions/AS2 Gateway, PV Intake, Analytics, and Safety Signals.

This all-in-one platform is driving the market forward. Furthermore, organizational initiatives support the growth of emerging markets like Brazil. For instance, a collaborative Patient Safety and PV program was introduced in Brazil, involving the pharmaceutical industry, academia, clinical practice, and health authorities. Offered by FIPFARMA (Fundacao Instituto de Pesquisas Farmaceuticas) and Pharmacy College (Universidade de Sao Paulo), the program conducted a 30-hour online course in two cohorts (2020 and 2022). It covered crucial topics, such as Healthcare and Pharmacovigilance Overview, Drug Safety & Management, and Patient Safety Culture. Workshops addressed real Challenges Healthcare Professionals (HCPs) faced and encouraged collaborative problem-solving.

Video conferences effectively engaged and educated HCPs, facilitating knowledge sharing and promoting a mindset shift. This initiative positively impacted participants and enhanced PV practices in Brazil. Key pharma companies in developed nations are concentrating on outsourcing PV services to decrease costs and reduce operational expenses. This is expected to create an opportunity for Contact Research Organizations (CROs) in developing territories to acquire more industry share. Manufacturers are renovating their product development procedures to fulfill the growing patient needs worldwide. These factors are predicted to augment the demand for PV services over the forecast period.

Furthermore, PV industry players are implementing strategies like acquisitions, collaborations, expansions, and product launches to broaden their offerings and expand their market presence. For example, in February 2022, Ergomed plc, a specialized services provider to the pharmaceutical industry, acquired ADAMAS Consulting Group Limited. ADAMAS is an international consultancy that offers quality assurance services in pharmaceutical manufacturing, clinical trial auditing, and PV systems. The acquisition, valued at £25.6 million (in pounds), is expected to favor Ergomed's earnings, with further growth and strategic advantages anticipated in the future.

Pharmacovigilance Market Report Highlights:

• Phase IV dominated the market with a revenue share of over 75.90% in 2024. This was driven by increased ADR incidents and post-marketing surveillance
• contract outsourcing segment held the largest market share in in the service provider segment in 2024, as pharmaceutical organizations aimed to reduce operational costs by outsourcing services
• Spontaneous reporting segment dominated the pharmacovigilance market in 2024 with the largest share. Its applications include efficient and cost-effective detection of new, serious, and rare ADRs
• Oncology held the largest share of over 27.14% in the therapeutic area segment in 2024, fueled by biopharmaceutical companies' research efforts in chronic cancer treatments
• Case data management is anticipated to grow at the fastest CAGR in the process flow segment during the forecast period
• The biotechnology companies segment is expected to grow at the fastest CAGR during the forecast period. This is due to their focus on R&D for novel products, such as biologics, therapies, and gene therapies
• North America held the largest revenue share of over 32.11% in 2024 due to investments in new drug development, favorable regulations, and a strong presence of research units and clinical trials
• Companies are adopting strategies like new product launches, collaborations, and acquisitions to gain a competitive advantage

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Life Cycle
  • 1.2.2. Service Provider
  • 1.2.3. Type
  • 1.2.4. Process Flow
  • 1.2.5. Therapeutic area
  • 1.2.6. End use
  • 1.2.7. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
    • 1.5.4.1. Details of Primary Research
    • 1.5.4.2. Data for primary interviews in North America
    • 1.5.4.3. Data for Primary Interviews in Europe
    • 1.5.4.4. Data for Primary Interviews in APAC
    • 1.5.4.5. Data for Primary Interviews in Latin America
    • 1.5.4.6. Data for Primary Interviews in MEA
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Report Objectives
  • 1.10.1. Objective-1
  • 1.10.2. Objective-2

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
  • 2.2.1. Segment Snapshot (Product Life Cycle & Type)
  • 2.2.2. Segment Snapshot (Process Flow & Therapeutic Area)
  • 2.2.3. Segment Snapshot (End Use)
  • 2.2.4. Competitive Landscape Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing drug consumption and drug development rates
    • 3.2.1.2. Increasing incidence of ADR and drug toxicity
    • 3.2.1.3. Increasing trend of outsourcing pharmacovigilance services
    • 3.2.1.4. Increasing externalization of clinical trial studies by large
    • 3.2.1.5. Increasing Regulatory Burden on Manufacturers
    • 3.2.1.6. Introduction of technologically advanced software services
      • 3.2.1.6.1. Key focus areas for the pharmaceutical/healthcare companies
      • 3.2.1.6.2. Adoption of technological advancements in Life sciences industry
      • 3.2.1.6.3. Published Survey insights - related to adoption of pharmacovigilance automation
    • 3.2.1.7. Rising investment on R&D by healthcare companies
    • 3.2.1.8. Partnerships and collaborations between market players
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Shortage of skilled labor
    • 3.2.2.2. Expensive technology for small and mid-sized player
    • 3.2.2.3. Lack of recognition
    • 3.2.2.4. Scarcity of integration standards
  • 3.2.3. Industry Opportunity Analysis
  • 3.2.4. Industry Challenge Analysis
• 3.3. Porter's Five Forces Analysis
  • 3.3.1. Supplier power
  • 3.3.2. Buyer power
  • 3.3.3. Substitution threat
  • 3.3.4. Threat of new entrant
  • 3.3.5. Competitive rivalry
• 3.4. PESTLE Analysis
• 3.5. Value Chain Analysis
  • 3.5.1. Preclinical
  • 3.5.2. Clinical
  • 3.5.3. PMA
• 3.6. Mapping of Life Cycle Against Service Offering and Their Demand
• 3.7. Regulatory Framework
  • 3.7.1. List of regulatory bodies by Country
• 3.8. Pricing Models
  • 3.8.1. Drug safety budget allocation by activities
  • 3.8.2. By development phase
  • 3.8.3. By therapeutic area
  • 3.8.4. Pricing level
    • 3.8.4.1. Project management
    • 3.8.4.2. Case processing
    • 3.8.4.3. ADR Reporting
    • 3.8.4.4. Medical writing
    • 3.8.4.5. Drug safety management
• 3.9. Technology Timeline Overview
  • 3.9.1. Changing Technology & Adoption
  • 3.9.2. Current Technology Landscape of PV
  • 3.9.3. IQVIA's AI-Driven Transformation in Pharmacovigilance
  • 3.9.4. Tech Mahindra's AI-Driven Pharmacovigilance Solution in
  • 3.9.5. The evolving PV workload with AI assistance
  • 3.9.6. Social Media
    • 3.9.6.1. Literature screening
    • 3.9.6.2. Automation and AI
    • 3.9.6.3. Big data analytics in PV
• 3.10. COVID 19 Impact Analysis
  • 3.10.1. Developments & Strategic Outcomes
    • 3.10.1.1. Regulatory requirements/changes due to covid-19
    • 3.10.1.2. Strategies implemented by companies
      • 3.10.1.2.1. IQVIA
      • 3.10.1.2.2. IBM Corporation
      • 3.10.1.2.3. ArisGlobal
      • 3.10.1.2.4. PAREXEL International Corporation
      • 3.10.1.2.5. Bioclinica
      • 3.10.1.2.6. Pharmaceutical Product Development (PPD)
      • 3.10.1.2.7. ICON, plc
      • 3.10.1.2.8. PRA Health Sciences
      • 3.10.1.2.9. Linical Accelovance
      • 3.10.1.2.10. Laboratory Corporation of America Holdings
• 3.11. Market Trend:
  • 3.11.1. Scaling of resources
  • 3.11.2. Automation in Pharmacovigilance
• 3.12. Impact of Inflation
• 3.13. Case Studies
  • 3.13.1. Potential Customers
  • 3.13.2. Notable Use Cases
  • 3.13.3. Case Study 1
    • 3.13.3.1. Part 1
    • 3.13.3.2. Part 2
  • 3.13.4. Case Study 2
  • 3.13.5. Case Study 3
  • 3.13.6. Case Study 4

Chapter 4. Pharmacovigilance Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Product Market Share Movement Analysis, 2024 & 2030
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.3.1. Preclinical
    • 4.3.1.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.2. Phase I
    • 4.3.2.1. Phase I market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.3. Phase II
    • 4.3.3.1. Phase II market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.4. Phase III
    • 4.3.4.1. Phase III market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.5. Phase IV
    • 4.3.5.1. Phase IV market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pharmacovigilance Market: Service Provider Estimates & Trend Analysis

• 5.1. Service Provider Dashboard
• 5.2. Service Provider Market Share Movement Analysis, 2024 & 2030
• 5.3. Market Size & Forecasts and Trend Analysis, by Service Provider, 2018 to 2030 (USD Million)
• 5.4. In House
  • 5.4.1. In-house market, 2018 - 2030 (USD Million)
• 5.5. Contract Outsourcing
  • 5.5.1. Contract Outsourcing market, 2018 - 2030 (USD Million)

Chapter 6. Pharmacovigilance Market: Type Estimates & Trend Analysis

• 6.1. Type Segment Dashboard
• 6.2. Type Market Share Movement Analysis, 2024 & 2030
• 6.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 6.4. Spontaneous Reporting
  • 6.4.1. Spontaneous Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Intensified ADR Reporting
  • 6.5.1. Intensified ADR Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.6. Targeted Spontaneous Reporting
  • 6.6.1. Targeted spontaneous reporting market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.7. Cohort Event Monitoring (CEM)
  • 6.7.1. CEM market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.8. EHR Mining
  • 6.8.1. EHR Mining market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pharmacovigilance Market: Process Flow Estimates & Trend Analysis

• 7.1. Process Flow Segment Dashboard
• 7.2. Process Flow Market Share Movement Analysis, 2024 & 2030
• 7.3. Market Size & Forecasts and Trend Analysis, by Process Flow, 2018 to 2030 (USD Million)
• 7.4. Case data management
  • 7.4.1. Case data management market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.1.1. Case logging
      • 7.4.1.1.1. Case logging market, 2018 - 2030 (USD Million)
    • 7.4.1.2. Case data analysis
      • 7.4.1.2.1. Case data analysis market, 2018 - 2030 (USD Million)
    • 7.4.1.3. Medical reviewing and reporting
      • 7.4.1.3.1. Medical reviewing and reporting market, 2018 - 2030 (USD Million)
• 7.5. Signal detection
  • 7.5.1. Signal detection market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.1.1. Adverse Event Logging
      • 7.5.1.1.1. Adverse event logging market, 2018 - 2030 (USD Million)
    • 7.5.1.2. Adverse Event Analysis
      • 7.5.1.2.1. Adverse Event Analysis market, 2018 - 2030 (USD Million)
    • 7.5.1.3. Adverse Event Review & Reporting
      • 7.5.1.3.1. Adverse Event Review & Reporting market, 2018 - 2030 (USD Million)
• 7.6. Risk Management System
  • 7.6.1. Risk Management System market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.1.1. Risk Evaluation System
      • 7.6.1.1.1. Risk Evaluation market, 2018 - 2030 (USD Million)
    • 7.6.1.2. Risk Mitigation System
      • 7.6.1.2.1. Risk Mitigation market, 2018 - 2030 (USD Million)

Chapter 8. Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis

• 8.1. Therapeutic Area Segment Dashboard
• 8.2. Therapeutic Area Market Share Movement Analysis, 2024 & 2030
• 8.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
• 8.4. Oncology
  • 8.4.1. Oncology market, 2018 - 2030 (USD Million)
• 8.5. Neurology
  • 8.5.1. Neurology market, 2018 - 2030 (USD Million)
• 8.6. Respiratory Systems
  • 8.6.1. Respiratory Systems market, 2018 - 2030 (USD Million)
• 8.7. Others
  • 8.7.1. Other market, 2018 - 2030 (USD Million)
• 8.8. Neurology

Chapter 9. Pharmacovigilance Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Dashboard
• 9.2. Regional Market: Key Takeaways
• 9.3. North America
  • 9.3.1. North America Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.3.2. U.S.
    • 9.3.2.1. Key country dynamic
    • 9.3.2.2. Regulatory framework
    • 9.3.2.3. Competitive insights
    • 9.3.2.4. U.S. Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key country dynamic
    • 9.3.3.2. Regulatory framework
    • 9.3.3.3. Competitive insights
    • 9.3.3.4. Canada Pharmacovigilance market estimates and forecasts, 2018 - 2030
  • 9.3.4. Mexico
    • 9.3.4.1. Key country dynamic
    • 9.3.4.2. Regulatory framework
    • 9.3.4.3. Competitive insights
    • 9.3.4.4. Mexico Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. Europe Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamic
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Competitive insights
    • 9.4.2.4. Germany Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.3. UK
    • 9.4.3.1. Key country dynamic
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Competitive insights
    • 9.4.3.4. UK Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key country dynamic
    • 9.4.4.2. Regulatory framework
    • 9.4.4.3. Competitive insights
    • 9.4.4.4. France Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key country dynamic
    • 9.4.5.2. Regulatory framework
    • 9.4.5.3. Competitive insights
    • 9.4.5.4. Italy Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key country dynamic
    • 9.4.6.2. Regulatory framework
    • 9.4.6.3. Competitive insights
    • 9.4.6.4. Spain Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.7. Russia
    • 9.4.7.1. Key country dynamic
    • 9.4.7.2. Regulatory framework
    • 9.4.7.3. Competitive insights
    • 9.4.7.4. Russia Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamic
    • 9.4.8.2. Regulatory framework
    • 9.4.8.3. Competitive insights
    • 9.4.8.4. Denmark Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.9. Sweden
    • 9.4.9.1. Key country dynamic
    • 9.4.9.2. Regulatory framework
    • 9.4.9.3. Competitive insights
    • 9.4.9.4. Sweden Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.10. Norway
    • 9.4.10.1. Key country dynamic
    • 9.4.10.2. Regulatory framework
    • 9.4.10.3. Competitive insights
    • 9.4.10.4. Norway Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.2. Japan
    • 9.5.2.1. Key country dynamic
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Competitive insights
    • 9.5.2.4. Japan Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.3. China
    • 9.5.3.1. Key country dynamic
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Competitive insights
    • 9.5.3.4. China Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key country dynamic
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Competitive insights
    • 9.5.4.4. India Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamic
    • 9.5.5.2. Regulatory framework
    • 9.5.5.3. Competitive insights
    • 9.5.5.4. South Korea Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.6. Australia
    • 9.5.6.1. Key country dynamic
    • 9.5.6.2. Regulatory framework
    • 9.5.6.3. Competitive insights
    • 9.5.6.4. Australia Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.7. Thailand
    • 9.5.7.1. Key country dynamic
    • 9.5.7.2. Regulatory framework
    • 9.5.7.3. Competitive insights
    • 9.5.7.4. Thailand Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Latin America Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key country dynamic
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Competitive insights
    • 9.6.2.4. Brazil Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.6.2.5. (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key country dynamic
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive insights
    • 9.6.3.4. Argentina Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.7. MEA
  • 9.7.1. MEA Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Key country dynamic
    • 9.7.2.2. Regulatory framework
    • 9.7.2.3. Competitive insights
    • 9.7.2.4. South Africa Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7.3. Saudi Arabia
    • 9.7.3.1. Key country dynamic
    • 9.7.3.2. Regulatory framework
    • 9.7.3.3. Competitive insights
    • 9.7.3.4. Saudi Arabia Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7.4. UAE
    • 9.7.4.1. Key country dynamic
    • 9.7.4.2. Regulatory framework
    • 9.7.4.3. Competitive insights
    • 9.7.4.4. UAE Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key country dynamic
    • 9.7.5.2. Regulatory framework
    • 9.7.5.3. Competitive insights
    • 9.7.5.4. Kuwait Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 10. Pharmacovigilance Market: Competitive Analysis

• 10.1. Market Participant Categorization
• 10.2. Public Companies
  • 10.2.1. Company Market Position Analysis
  • 10.2.2. Company Market Share Analysis
• 10.3. Competitive Factors and Strategies
  • 10.3.1. Increasing Strategic Collaborations and Product Launches
  • 10.3.2. Strategic Government initiatives, including collaborations
  • 10.3.3. Competitors increased PV Awareness programs
  • 10.3.4. Competitors increased collaboration and outsourcing of operations
  • 10.3.5. Consolidation Trends

Chapter 11. Competitive Landscape

• 11.1. Company Profiles
  • 11.1.1. Accenture
    • 11.1.1.1. Overview
    • 11.1.1.2. Financial performance
    • 11.1.1.3. Product benchmarking
    • 11.1.1.4. Strategic initiatives
  • 11.1.2. IQVIA Inc.
    • 11.1.2.1. Overview
    • 11.1.2.2. Financial performance
    • 11.1.2.3. Product benchmarking
    • 11.1.2.4. Strategic initiatives
  • 11.1.3. Cognizant
    • 11.1.3.1. Overview
    • 11.1.3.2. Financial performance
    • 11.1.3.3. Product benchmarking
    • 11.1.3.4. Strategic initiatives
  • 11.1.4. Clinquest Group B.V. (Linical Americas)
    • 11.1.4.1. Overview
    • 11.1.4.2. Financial performance
    • 11.1.4.3. Product benchmarking
    • 11.1.4.4. Strategic initiatives
  • 11.1.5. IBM
    • 11.1.5.1. Overview
    • 11.1.5.2. Financial performance
    • 11.1.5.3. Product benchmarking
    • 11.1.5.4. Strategic initiatives
  • 11.1.6. Laboratory Corporation of America Holdings
    • 11.1.6.1. Overview
    • 11.1.6.2. Financial performance
    • 11.1.6.3. Product benchmarking
    • 11.1.6.4. Strategic initiatives
  • 11.1.7. ArisGlobal
    • 11.1.7.1. Overview
    • 11.1.7.2. Financial performance
    • 11.1.7.3. Product benchmarking
    • 11.1.7.4. Strategic initiatives
  • 11.1.8. Capgemini
    • 11.1.8.1. Overview
    • 11.1.8.2. Financial performance
    • 11.1.8.3. Product benchmarking
    • 11.1.8.4. Strategic initiatives
  • 11.1.9. ITClinical
    • 11.1.9.1. Overview
    • 11.1.9.2. Financial performance
    • 11.1.9.3. Products & Services benchmarking
    • 11.1.9.4. Strategic initiatives
  • 11.1.10. ICON plc.
    • 11.1.10.1. Overview
    • 11.1.10.2. Financial performance
    • 11.1.10.3. Product benchmarking
    • 11.1.10.4. Strategic initiatives
  • 11.1.11. TAKE Solutions Limited
    • 11.1.11.1. Overview
    • 11.1.11.2. Financial performance
    • 11.1.11.3. Product benchmarking
    • 11.1.11.4. Strategic initiatives
  • 11.1.12. Parexel International (MA) Corporation
    • 11.1.12.1. Overview
    • 11.1.12.2. Financial performance
    • 11.1.12.3. Product benchmarking
    • 11.1.12.4. Strategic initiatives
  • 11.1.13. Wipro
    • 11.1.13.1. Overview
    • 11.1.13.2. Financial performance
    • 11.1.13.3. Product benchmarking
    • 11.1.13.4. Strategic initiatives
  • 11.1.14. United BioSource LLC
    • 11.1.14.1. Overview
    • 11.1.14.2. Financial performance
    • 11.1.14.3. Product benchmarking
    • 11.1.14.4. Strategic initiatives
  • 11.1.15. BioClinica Inc. (Clario)
    • 11.1.15.1. Overview
    • 11.1.15.2. Financial performance
    • 11.1.15.3. Product benchmarking
    • 11.1.15.4. Strategic initiatives
  • 11.1.16. ClinChoice (formerly FMD K&L)
    • 11.1.16.1. Overview
    • 11.1.16.2. Financial performance
    • 11.1.16.3. Product benchmarking
    • 11.1.16.4. Strategic initiatives

Chapter 12. Winning Strategies

• 12.1. Key Winning / Scoring Criteria
  • 12.1.1. By Categories
    • 12.1.1.1. Pharmaceuticals
    • 12.1.1.2. Biotech companies
    • 12.1.1.3. Medical device companies
  • 12.1.2. Key Vendor Selection Factors
    • 12.1.2.1. By Category
    • 12.1.2.2. BY Company size
      • 12.1.2.2.1.1. Key Takeaways

Chapter 13. Switching Cost Analysis

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. North America Pharmacovigilance market, by country, 2018 - 2030 (USD Million)
• Table 4. North America Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
• Table 5. North America Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 6. North America Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 7. North America Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 8. North America Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 9. North America Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 10. U.S. Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 11. U.S. Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 12. U.S. Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 13. U.S. Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 14. U.S. Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 15. U.S. Pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
• Table 16. Canada Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 17. Canada Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 18. Canada Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 19. Canada Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 20. Canada Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 21. Canada Pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
• Table 22. Mexico Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 23. Mexico Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 24. Mexico Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 25. Mexico Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 26. Mexico Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 27. Mexico Pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
• Table 28. Europe Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 29. Europe Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 30. Europe Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 31. Europe Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 32. Europe Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 33. Europe Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 34. UK Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 35. UK Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 36. UK Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 37. UK Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 38. UK Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 39. UK Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 40. Germany Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 41. Germany Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 42. Germany Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 43. Germany Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 44. Germany Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 45. Germany Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 46. France Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 47. France Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 48. France Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 49. France Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 50. France Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 51. France Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 52. Italy Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 53. Italy Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 54. Italy Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 55. Italy Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 56. Italy Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 57. Italy Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 58. Spain Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 59. Spain Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 60. Spain Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 61. Spain Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 62. Spain Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 63. Spain Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 64. Russia Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 65. Russia Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 66. Russia Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 67. Russia Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 68. Russia Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 69. Russia Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 70. Norway Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 71. Norway Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 72. Norway Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 73. Norway Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 74. Norway Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 75. Norway Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 76. Sweden Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 77. Sweden Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 78. Sweden Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 79. Sweden Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 80. Sweden Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 81. Sweden Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 82. Denmark Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 83. Denmark Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 84. Denmark Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 85. Denmark Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 86. Denmark Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 87. Denmark Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 88. Asia Pacific Pharmacovigilance market, by country, 2018 - 2030 (USD Million)
• Table 89. Asia Pacific Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 90. Asia Pacific Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 91. Asia Pacific Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 92. Asia Pacific Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 93. Asia Pacific Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 94. Asia Pacific Pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
• Table 95. Japan Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 96. Japan Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 97. Japan Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 98. Japan Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 99. Japan Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 100. China Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 101. China Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 102. China Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 103. China Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 104. China Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 105. China Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 106. India Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 107. India Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 108. India Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 109. India Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 110. India Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 111. India Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 112. Australia Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 113. Australia Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 114. Australia Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 115. Australia Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 116. Australia Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 117. Australia Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 118. South Korea Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
• Table 119. South Korea Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 120. South Korea Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 121. South Korea Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 122. South Korea Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 123. South Korea Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 124. Thailand Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
• Table 125. Thailand Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 126. Thailand Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 127. Thailand Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 128. Thailand Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 129. Thailand Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 130. Latin America Pharmacovigilance market, by country, 2018 - 2030 (USD Million)
• Table 131. Latin America Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 132. Latin America Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 133. Latin America Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 134. Latin America Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 135. Latin America Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 136. Latin America Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 137. Brazil Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 138. Brazil Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 139. Brazil Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 140. Brazil Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 141. Brazil Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 142. Brazil Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 143. Argentina Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 144. Argentina Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 145. Argentina Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 146. Argentina Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 147. Argentina Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 148. Argentina Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 149. Middle East & Africa Pharmacovigilance market, by country, 2018 - 2030 (USD Million)
• Table 150. Middle East & Africa Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 151. Middle East & Africa Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 152. Middle East & Africa Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 153. Middle East & Africa Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 154. Middle East & Africa Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 155. Middle East & Africa Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 156. South Africa Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
• Table 157. South Africa Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 158. South Africa Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 159. South Africa Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 160. South Africa Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 161. South Africa Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 162. Saudi Arabia Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
• Table 163. Saudi Arabia Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 164. Saudi Arabia Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 165. Saudi Arabia Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 166. Saudi Arabia Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 167. Saudi Arabia Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 168. UAE Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 169. UAE Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 170. UAE Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 171. UAE Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 172. UAE Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 173. UAE Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 174. Kuwait Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 175. Kuwait Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 176. Kuwait Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 177. Kuwait Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 178. Kuwait Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 179. Kuwait Pharmacovigilance market, end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Pharmacovigilance market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market formulation & validation
• Fig. 6 Market research approaches
• Fig. 7 Value-chain-based sizing & forecasting
• Fig. 8 QFD modelling for market share assessment
• Fig. 9 Commodity flow analysis
• Fig. 10 Market snapshot
• Fig. 11 Market segmentation (USD Million)
• Fig. 12 Competitive landscape
• Fig. 13 Parent market outlook (In USD Billion)
• Fig. 14 Related/ancillary market outlook (In USD Billion)
• Fig. 15 Pharmacovigilance market dynamics
• Fig. 16 Pharmacovigilance market: Porter's five forces analysis
• Fig. 17 Pharmacovigilance market: PESTLE analysis
• Fig. 18 Pharmacovigilance market: product life cycle segment dashboard
• Fig. 19 Pharmacovigilance market: product life cycle market share analysis, 2024 & 2030
• Fig. 20 Preclinical market, 2018 - 2030 (USD Million)
• Fig. 21 Phase I market, 2018 - 2030 (USD Million)
• Fig. 22 Phase II market, 2018 - 2030 (USD Million)
• Fig. 23 Phase III market, 2018 - 2030 (USD Million)
• Fig. 24 Phase IV market, 2018 - 2030 (USD Million)
• Fig. 25 Pharmacovigilance market: Service provider movement analysis
• Fig. 26 Pharmacovigilance Service provider dashboard
• Fig. 27 Pharmacovigilance market: product life cycle segment dashboard
• Fig. 28 Pharmacovigilance market: product life cycle market share analysis, 2024 & 2030
• Fig. 29 In-house market, 2018 - 2030 (USD Million)
• Fig. 30 contract outsourcing market, 2018 - 2030 (USD Million)
• Fig. 31 Pharmacovigilance market: Type movement analysis
• Fig. 32 Pharmacovigilance type dashboard
• Fig. 33 Pharmacovigilance market: product life cycle segment dashboard
• Fig. 34 Pharmacovigilance market: product life cycle market share analysis, 2024 & 2030
• Fig. 35 Spontaneous reporting market, 2018 - 2030 (USD Million)
• Fig. 36 Intensified ADR reporting market, 2018 - 2030 (USD Million)
• Fig. 37 Targeted spontaneous reporting market, 2018 - 2030 (USD Million)
• Fig. 38 CEM market, 2018 - 2030 (USD Million)
• Fig. 39 EHR mining market, 2018 - 2030 (USD Million)
• Fig. 40 Pharmacovigilance market: process flow segment dashboard
• Fig. 41 Pharmacovigilance market: process flow market share analysis, 2024 & 2030
• Fig. 42 Case data management market, 2018 - 2030 (USD Million)
• Fig. 43 Case logging market, 2018 - 2030 (USD Million)
• Fig. 44 Case data analysis market, 2018 - 2030 (USD Million)
• Fig. 45 Medical reviewing and reporting market, 2018 - 2030 (USD Million)
• Fig. 46 Signal detection market, 2018 - 2030 (USD Million)
• Fig. 47 Adverse event logging market, 2018 - 2030 (USD Million)
• Fig. 48 Adverse event analysis market, 2018 - 2030 (USD Million)
• Fig. 49 Adverse event review & reporting market, 2018 - 2030 (USD Million)
• Fig. 50 Risk management system market, 2018 - 2030 (USD Million)
• Fig. 51 Risk Evaluation System market, 2018 - 2030 (USD Million)
• Fig. 52 Risk mitigation system market, 2018 - 2030 (USD Million)
• Fig. 53 Pharmacovigilance market: therapeutic area segment dashboard
• Fig. 54 Pharmacovigilance market: therapeutic area market share analysis, 2024 & 2030
• Fig. 55 Oncology market, 2018 - 2030 (USD Million)
• Fig. 56 Neurology market, 2018 - 2030 (USD Million)
• Fig. 57 Cardiology market, 2018 - 2030 (USD Million)
• Fig. 58 Respiratory systems market, 2018 - 2030 (USD Million)
• Fig. 59 Others market, 2018 - 2030 (USD Million)
• Fig. 60 Pharmacovigilance market: end use segment dashboard
• Fig. 61 Pharmacovigilance market: end use market share analysis, 2024 & 2030
• Fig. 62 Pharmaceuticals market, 2018 - 2030 (USD Million)
• Fig. 63 Biotechnology companies' market, 2018 - 2030 (USD Million)
• Fig. 64 Medical device manufacturers market, 2018 - 2030 (USD Million)
• Fig. 65 Others market, 2018 - 2030 (USD Million)
• Fig. 66 Pharmacovigilance market revenue, by region
• Fig. 67 Regional marketplace: Key takeaways
• Fig. 68 North America Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 69 Key country dynamics
• Fig. 70 US Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 71 Key country dynamics
• Fig. 72 Canada Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 73 Key country dynamics
• Fig. 74 Mexico Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 75 Key country dynamics
• Fig. 76 Europe Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 77 Key country dynamics
• Fig. 78 UK Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 79 Key country dynamics
• Fig. 80 Germany Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 81 Key country dynamics
• Fig. 82 France Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 83 Key country dynamics
• Fig. 84 Italy Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 85 Key country dynamics
• Fig. 86 Spain Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 87 Key country dynamics
• Fig. 88 Norway Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 89 Key country dynamics
• Fig. 90 Sweden Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 91 Key country dynamics
• Fig. 92 Denmark Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 93 Asia Pacific Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 94 Key country dynamics
• Fig. 95 Japan Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 96 Key country dynamics
• Fig. 97 China Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 98 Key country dynamics
• Fig. 99 India Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 100 Key country dynamics
• Fig. 101 Australia Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 102 Key country dynamics
• Fig. 103 South Korea Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 104 Key country dynamics
• Fig. 105 Thailand Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 106 Latin America Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 107 Key country dynamics
• Fig. 108 Brazil Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 109 Key country dynamics
• Fig. 110 Argentina Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 111 Key country dynamics
• Fig. 112 MEA Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 113 Key country dynamics
• Fig. 114 South Africa Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 115 Key country dynamics
• Fig. 116 Saudi Arabia Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 117 Key country dynamics
• Fig. 118 UAE Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 119 Key country dynamics
• Fig. 120 Kuwait healthcare information system market, 2018 - 2030 (USD Million)
• Fig. 121 Key country dynamics
• Fig. 122 Company categorization
• Fig. 123 Company market position analysis
• Fig. 124 Strategic framework